HC Wainwright & Co. Upgrades Sutro Biopharma to Buy, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 90.1%

Neg 0% Neu 0% Pos 90.1%

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Buy and raises the price target from $10 to $28.